Navigation Links
Exacerbations in COPD: One thing leads to another
Date:2/19/2009

New research shows that individual exacerbations in chronic obstructive lung disease (COPD) themselves increase the likelihood of repeat exacerbations, even after five days of full, asymptomatic recoverybad news for patients with COPD, where each exacerbation can drive the progression of the disease.

"This concept that exacerbations are not random has important implication for the analysis of clinical trial data and identifies a specific high-risk period for recurrent exacerbation during which preventative interventions might be targeted," wrote lead author, John Hurst, M.D., of the Royal Free and University College Medical School, in London.

The results appeared in the first issue for March of the American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society.

In patients with COPD, exacerbations are generally defined as an acute worsening of symptoms. Exacerbations in and of themselves are inherently dangerous and can lead to hospitalization and serious complications. But beyond their acute dangers, exacerbations drive lung function decline, and many patients never recover their baseline level of lung function after exacerbations. Prior to this research, however, exacerbations were assumed to be isolated events unrelated to one another despite observational data that suggested a dependency.

To test the validity of this assumption, which not only informs treatment plans for patients with COPD, but also forms the basis of research design and analysis, Dr. Hurst and colleagues analyzed daily symptom diaries that were kept for at least one year by 297 COPD patients, describing nearly 2,000 distinct exacerbation events. Two or more new or worsening symptoms, one of which must be "major" (e.g., dyspnea, more sputum, or a change in color of sputum) constituted an exacerbation, and after five days of symptoms reverting to baseline severity, the exacerbation was considered to be over. A second exacerbation occurring within an eight-week period was considered to be a recurrent exacerbation. The researchers further analyzed seasonality of exacerbations, comparing their winter (November to January) frequency with their summer (June-August) frequency.

In addition to the finding that exacerbations were clustered in time within individuals, the researchers found that they were significantly more common in the winter than the summer. They also noted that "isolated" exacerbations tended on average to be about 25 percent more severe than the first of serial exacerbations.

But most importantly, the researchers identified an eight-week period of time during which monitoring and follow-up is crucial to prevent or minimize further exacerbations in the COPD patient. "Our finding of a high-risk period for recurrent exacerbation may be important in guiding patient follow-up," wrote Dr. Hurst.

"The mechanisms of exacerbation recurrence remain unexplored, and it is unknown whether recurrence is due to persistence of an existing organism or to acquisition of a new one," noted Dr. Hurst. However, there are some clues that may guide future research. "The failure to eradicate bacteria with exacerbation therapy has been associated with an incomplete recovery in inflammatory markers and we have recently reported a relationship between elevated C-reactive protein during the recovery period of an initial exacerbation and shorter time to the next." Furthermore, the paper noted that "symptoms more typical of viral infection are significantly more common during isolated events."

"This knowledge is very important for physicians," wrote Shawn D. Aaron, M.D., of the Ottawa Health Research Institute, in Canada, in an editorial in the same issue of the journal. "Clinicians should now be aware that their patients with COPD who experience an exacerbation may be particularly 'brittle' during a subsequent eight-week period. Close monitoring and follow-up during this time would hopefully lead to earlier therapy for recurrent exacerbations that may improve clinical outcomes."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.
2. Long-term antibiotics reduce COPD exacerbations, raise questions
3. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
4. Philippine Birthing Centers Help New Mothers, Healthy Infants
5. Nothing But Nets and Union of Reform Judaism Help Save Lives in Kenya
6. Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies
7. Sleep disordered breathing and obesity: Independent effects, causes
8. ING and Fit Miami Foundation Name Winners of ING Run For Something Better Student Essay Contest
9. Vicks VapoRub Linked to Infant Breathing Problems
10. KnowYourTeeth.com Launches as the Internets New Go-To Resource for All Things Dental
11. Breathing easier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, ... with The Jensie Gran Fondo of Marin. For the second year in a ... broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... India , February 23, 2017 ... Imaging Market by Product (X-ray Imaging Digital, Analog), MRI ... Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging ... the report studies the global market over the forecast ... to reach ~USD 36.43 Billion by 2021, at a ...
Breaking Medicine Technology: